4-Allyl-6-oxa-noribogainalog

4-Allyl-6-oxa-noribogainalog
Clinical data
Other names4-Allyl-6-oxanoribogainalog; 4-Allyloxa-noribogainalog; "Compound 23"
Drug classκ-Opioid receptor agonist
ATC code
  • None
Identifiers
  • 3-methyl-4-prop-2-enyl-1,2,4,5-tetrahydro-[1]benzofuro[2,3-d]azepin-9-ol
PubChem CID
Chemical and physical data
FormulaC16H19NO2
Molar mass257.333 g·mol−1
3D model (JSmol)
  • CN1CCC2=C(CC1CC=C)OC3=C2C=C(C=C3)O
  • InChI=1S/C16H19NO2/c1-3-4-11-9-16-13(7-8-17(11)2)14-10-12(18)5-6-15(14)19-16/h3,5-6,10-11,18H,1,4,7-9H2,2H3
  • Key:JNHYXOGJXDHIOU-UHFFFAOYSA-N

4-Allyl-6-oxa-noribogainalog is a κ-opioid receptor (KOR) agonist of the oxa-ibogalog family related to oxa-noribogaine.[1][2] It is a highly potent full agonist of the KOR, with an EC50Tooltip half-maximal effective concentration of 1 nM and an EmaxTooltip maximal efficacy of 103% in a G protein BRET assay.[1][2] This is dramatically more potent than oxa-noribogaine or noribogaine at the KOR in the same assay per another study by the same group (EC50 (Emax) = 43 nM (82%) and 6,100 nM (52%), respectively).[3][2] The drug shows considerable selectivity for activation of the KOR over activation of the μ- and δ-opioid receptors.[1][2] 4-Allyl-6-oxa-noribogainalog was the most potent KOR agonist in a series of oxa-ibogalog compounds.[1][2] It was patented by Dalibor Sames and colleagues in 2025, with Sames being a co-founder of Gilgamesh Pharmaceuticals.[1][2]

See also

References

  1. 1 2 3 4 5 Renner AC, Kargbo RB (January 2026). "Advances in Psychedelic Therapeutics: Multimodal Iboga Analogs, EEG-Guided Psilocybin Dosing, and Optimized Harmine-DMT Formulations". ACS Medicinal Chemistry Letters. 17 (1): 72–74. doi:10.1021/acsmedchemlett.5c00714. PMC 12794085. PMID 41531985.
  2. 1 2 3 4 5 6 WO 2025166273A1, Sames D, Havel V, "Novel analogs of oxa-iboga class of therapeutics", published 7 August 2025, assigned to Columbia University in the City of New York
  3. ↑ Havel V, Kruegel AC, Bechand B, McIntosh S, Stallings L, Hodges A, et al. (September 2024). "Oxa-Iboga alkaloids lack cardiac risk and disrupt opioid use in animal models". Nature Communications. 15 (1) 8118. Bibcode:2024NatCo..15.8118H. doi:10.1038/s41467-024-51856-y. PMC 11415492. PMID 39304653.